Would you offer adjuvant chemotherapy to a premenopausal patient with ER/PR+ breast cancer, nodal micrometastasis, low OncotypeDx score but also BRCA2 carrier?
Answer from: Medical Oncologist at Academic Institution
A breast cancer developing in a BRCA2 mutation cancer has the same prognosis as a non-mutation carrier (Robson et al., PMID 14680495), I would follow the low Oncotype score (assuming it is not 21-25) and treat her accordingly. If child-bearing is not a concern, and she is over 35 years, then bilater...
Sign in or Register to read more